Preclinical development of novel small molecule malaria drugs that overcome drug

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$600,000.00
Award Year:
2011
Program:
STTR
Phase:
Phase I
Contract:
1R41AI094959-01
Agency Tracking Number:
R41AI094959
Solicitation Year:
2011
Solicitation Topic Code:
NIAID
Solicitation Number:
PA10-124
Small Business Information
DESIGNMEDIX, INC.
2828 Corbett Ave Suite 140A, PORTLAND, OR, -
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
623389009
Principal Investigator:
DAVID PEYTON
(503) 725-3875
peyton@designmedix.com
Business Contact:
SANDRA SHOTWELL
(503) 771-0173
shotwell@designmedix.com
Research Institution:
PORTLAND STATE UNIVERSITY

PORTLAND STATE UNIVERSITY
BOX 751
PORTLAND, OR, 97207-
() -
Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): The worldwide health problem created by malaria has been made more difficult by the spread of drug- resistant parasites. This project initiates preclinical development of one or more candidate(s) from an innovative newclass of potent antimalarials designed to overcome drug resistance. We have developed an orally available and inexpensive class of novel drugs that act against both chloroquine-resistant and chloroquine-sensitive malaria. A small set of carefully-selectedcandidates will be advanced through preclinical testing, leading to the selection of a single drug for a pre-Investigational New Drug meeting with the Food and Drug Administration. With guidance from the Food and Drug Administration, pharmacokinetics, pharmacodynamics, pharmacology, and toxicity evaluations will be performed in both rats and monkeys in phase II of this work. The overall goal will be completion of preclinical studies leading to approval of the Investigative New Drug (IND) application for a drug to be used in a Phase-1 human clinical trial. PUBLIC HEALTH RELEVANCE: Malaria is a disease that infects about half a billion people annually, and kills nearly one million, most of whom are children or pregnant women. The impact of malaria is increasing, partly because the parasite that causes malaria has evolved into strains that are resistant to the best current drugs for treating the disease. This project involves preclinical evaluation of novel drugs designed to circumvent this resistance, paving the way toward approval for human clinical trials. The drug candidates show promising results in early studies, and are designed to be inexpensive as well as safe for all target groups, including pregnant women and children.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government